Cue Biopharma

137 articles about Cue Biopharma

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

  2/17/2021

  Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

• 

  Clinical Catch-Up: February 8-12

  2/15/2021

  It was a busy week for clinical trial announcements and news. Here’s a look.

• Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

  2/8/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA

• 

  Advances in the Battle Against Autoimmune Disease

  12/16/2020

  Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.

• Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference

  11/23/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020. The pre-recorded presentation will be available to

• Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

  11/19/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes an

• Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

  11/17/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, provided a business update for the third quarter of 2020.

• Cue Biopharma to Present at Upcoming Investor Conferences in November 2020

  11/11/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference

• Cue Biopharma to Host Business Update Call and Webcast

  11/10/2020

  Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, November 17, 2020 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s  website . Members of the

• Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the SITC’s 35th Anniversary Annual Meeting

  11/9/2020

  Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the SITC’s 35th Anniversary Annual Meeting

• Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

  10/19/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 35 th Anniversary Annual Meeting (SITC 2020). Presentation Details: Title: Immuno-STATs: Leveraging protein engineering to expand and track antigen-sp

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Cue Biopharma Welcomes Tamar Howson to its Board of Directors

  9/17/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the appointment of Tamar Howson to its board of directors

• Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds

  9/15/2020

  Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the peer-reviewed publicat

• Cue Biopharma to Present at Upcoming Investor Conferences in September 2020

  9/3/2020

  Cue Biopharma, Inc. announced it will present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020 and the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 23, 2020.

• Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates

  8/31/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the second quarter of 2020.

• Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit

  8/24/2020

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™,

• Cue Biopharma to Host Business Update Call and Webcast - Aug 17, 2020

  8/17/2020

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced it will host a conference call and webcast to provide a business update on Monday, August 31, 2020 at 4:30 p.m. EDT.

• Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer

  7/28/2020

  CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of selecting a recommended Phase 2 dose